143 related articles for article (PubMed ID: 18824429)
21. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
22. Phase II study of weekly oxaliplatin and high-dose infusional 5-fluorouracil plus leucovorin in pretreated patients with metastatic colorectal cancer.
Chiara S; Nobile MT; Gozza A; Taveggia P; Heouaine A; Pastrone I; Percivale PL; Lionetto R; Sanguineti O; Rosso R
Anticancer Res; 2004; 24(1):355-60. PubMed ID: 15015621
[TBL] [Abstract][Full Text] [Related]
23. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
24. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma.
Boorjian SA; Milowsky MI; Kaplan J; Albert M; Cobham MV; Coll DM; Mongan NP; Shelton G; Petrylak D; Gudas LJ; Nanus DM
J Immunother; 2007 Sep; 30(6):655-62. PubMed ID: 17667529
[TBL] [Abstract][Full Text] [Related]
25. Suramin in combination with 5-fluorouracil (5-FU) and leucovorin (LV) in metastatic colorectal cancer patients resistant to 5-FU+LV-based chemotherapy.
Falcone A; Pfanner E; Brunetti I; Allegrini G; Lencioni M; Galli C; Masi G; Danesi R; Antonuzzo A; Del Tacca M; Conte PF
Tumori; 1998; 84(6):666-8. PubMed ID: 10080673
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Hutson TE; Molto L; Mekhail T; Elson P; Finke J; Tannenbaum C; Borden E; Dreicer R; Olencki T; Bukowski RM
Clin Cancer Res; 2003 Apr; 9(4):1354-60. PubMed ID: 12684404
[TBL] [Abstract][Full Text] [Related]
27. A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Desai AA; Vogelzang NJ; Rini BI; Ansari R; Krauss S; Stadler WM
Cancer; 2002 Oct; 95(8):1629-36. PubMed ID: 12365009
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
Rathmell WK; Malkowicz SB; Holroyde C; Luginbuhl W; Vaughn DJ
Am J Clin Oncol; 2004 Apr; 27(2):109-12. PubMed ID: 15057147
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer.
Zaniboni A; Simoncini E; Marpicati P; Montini E; Ferrari V; Marini G
J Chemother; 1989 Oct; 1(5):350-1. PubMed ID: 2585035
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.
Kish JA; Wolf M; Crawford ED; Leimert JT; Bueschen A; Neefe JR; Flanigan RC
Cancer; 1994 Aug; 74(3):916-9. PubMed ID: 8039119
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
Kobayashi K; Vokes EE; Vogelzang NJ; Janish L; Soliven B; Ratain MJ
J Clin Oncol; 1995 Sep; 13(9):2196-207. PubMed ID: 7666078
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma.
Small EJ; Frye JW; Wilkinson MJ; Carroll PR; Ernest ML; Stagg RJ
Cancer; 1994 Jun; 73(11):2803-7. PubMed ID: 8194022
[TBL] [Abstract][Full Text] [Related]
33. Interferon-alpha and 5-fluorouracil therapy in patients with metastatic renal cell cancer: an open multicenter trial. The Japanese Study Group Against Renal Cancer.
Igarashi T; Marumo K; Onishi T; Kobayashi M; Aiba K; Tsushima T; Ozono S; Tomita Y; Terachi T; Satomi Y; Kawamura J
Urology; 1999 Jan; 53(1):53-9. PubMed ID: 9886588
[TBL] [Abstract][Full Text] [Related]
34. Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.
Reyno LM; Egorin MJ; Eisenberger MA; Sinibaldi VJ; Zuhowski EG; Sridhara R
J Clin Oncol; 1995 Sep; 13(9):2187-95. PubMed ID: 7666077
[TBL] [Abstract][Full Text] [Related]
35. Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study.
Liu JH; Yang MH; Fan FS; Yen CC; Wang WS; Chang YH; Chen KK; Chen PM
Urology; 2001 Apr; 57(4):650-4. PubMed ID: 11306370
[TBL] [Abstract][Full Text] [Related]
36. Pilot trial of infusional 5-fluorouracil, interleukin-2, and subcutaneous interferon-alpha for advanced renal cell carcinoma.
Elias L; Binder M; Mangalik A; Clark D; Morrison B; Altobelli KK; Smith A
Am J Clin Oncol; 1999 Apr; 22(2):156-61. PubMed ID: 10199450
[TBL] [Abstract][Full Text] [Related]
37. Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study.
Falcone A; Pfanner E; Cianci C; Danesi R; Brunetti I; Del Tacca M; Conte PF
Cancer; 1995 Jan; 75(2):440-3. PubMed ID: 7812913
[TBL] [Abstract][Full Text] [Related]
38. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
Miglietta L; Canobbio L; Granetto C; Vannozzi MO; Esposito M; Boccardo F
J Cancer Res Clin Oncol; 1997; 123(7):407-10. PubMed ID: 9260594
[TBL] [Abstract][Full Text] [Related]
39. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
[TBL] [Abstract][Full Text] [Related]
40. Suramin in combination with mitomycin C in hormone-resistant prostate cancer. A phase II clinical study.
Rapoport BL; Falkson G; Raats JI; de Wet M; Lotz BP; Potgieter HC
Ann Oncol; 1993 Aug; 4(7):567-73. PubMed ID: 8363988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
